Clinical Trials Browser

Active not recruiting × Azacitidine × Other hematologic neoplasm × Clear all

NCT00392353 2026-04-13

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04284787 2026-04-13

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Phase 2 Active not recruiting

60 enrolled 11 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05453903 2026-04-13

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Phase 1 Active not recruiting

196 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04734990 2026-04-02

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase 1/2 Active not recruiting

24 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00658814 2026-03-31

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2 Active not recruiting

133 enrolled 10 charts

Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT01522976 2026-03-31

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Phase 2 Active not recruiting

282 enrolled 11 charts

Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1/2 Active not recruiting

40 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Clinical Trials

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

BEXMAB

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission

AGILE

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

REGAL

CULMINATE

Viale-a

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

TWT-202

Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia

ELEVATE

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

PEVOLAM

FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms

A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

AMADEUS

LAM-BDD